Improved Survival of Advanced-Stage Anaplastic Thyroid Cancer With Systemic Therapy.
ATC
anaplastic thyroid cancer
immunotherapy
systemic therapy
targeted therapy
thyroid
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
20 Aug 2024
20 Aug 2024
Historique:
revised:
03
07
2024
received:
08
02
2024
accepted:
06
08
2024
medline:
20
8
2024
pubmed:
20
8
2024
entrez:
20
8
2024
Statut:
aheadofprint
Résumé
Anaplastic thyroid cancer (ATC) is the most aggressive and fatal thyroid malignancy. Currently, there still exists a paucity of literature studying the relationship between available ATC-targeted therapy, immunotherapy, and survival. We aim to investigate how systemic therapies affect survival outcomes in ATC. A single-tertiary-institution chart review of patients diagnosed with advanced-stage ATC, and who underwent surgery as part of their treatment, was performed between 2000 and 2023, with 41 patients included. Demographics, clinical characteristics, and survival data were collected and analyzed via Kaplan-Meier and Cox proportional hazards analyses. 54% of patients were female, and average age was 67.4 years old. The most common mutations identified were BRAF (15 patients), p53 (9 patients), and p63 (2 patients). A total of 18 patients utilized targeted or immunotherapy, with Trametinib and Dabrafenib (9 patients) as the most common agents used. Two-year overall survival was 24%, and 5-year overall survival was 23%, with median survival time of 7.6 months. Kaplan-Meier analysis demonstrated improved survival in patients who received chemotherapy (p = 0.048). Cox proportional hazards analysis demonstrated that patients treated with immunotherapy or targeted therapy had a statistically significant increase in survival compared with patients who did not receive these therapies (p = 0.016). Additionally, females and those with a p63 mutation demonstrated improved survival outcomes (p = 0.010, p = 0.001). Targeted therapy and immunotherapy use should be strongly considered when treating patients with ATC. Further studies into novel drugs targeting immune checkpoints and combination therapy are needed to better optimize treatment of patients with ATC. 3 Laryngoscope, 2024.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDCD NIH HHS
ID : R25DC020151
Pays : United States
Informations de copyright
© 2024 The Author(s). The Laryngoscope published by Wiley Periodicals LLC on behalf of The American Laryngological, Rhinological and Otological Society, Inc.
Références
Mao Y, Xing M. Recent incidences and differential trends of thyroid cancer in the USA. Endocr Relat Cancer. 2016;23(4):313‐322.
Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol). 2010;22(6):486‐497. https://doi.org/10.1016/J.CLON.2010.03.013.
Molinaro E, Romei C, Biagini A, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol. 2017;13(11):644‐660. https://doi.org/10.1038/NRENDO.2017.76.
Tan RK, Finley RK, Driscoll D, Bakamjian V, Hicks WL, Shedd DP. Anaplastic carcinoma of the thyroid: a 24‐year experience. Head Neck. 1995;17(1):41‐48. https://doi.org/10.1002/HED.2880170109.
Haigh PI, Ituarte PHWH. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer. 2001;91(12):2335‐2342.
Lo CY, Lam KY, Wan KY. Anaplastic carcinoma of the thyroid. Am J Surg. 1999;177(4):337‐339. https://doi.org/10.1016/S0002-9610(99)00052-5.
Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg. 2001;25(5):617‐622. https://doi.org/10.1007/S002680020166.
Xu B, Fuchs T, Dogan S, et al. Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases. Thyroid. 2020;30(10):1505‐1517. https://doi.org/10.1089/THY.2020.0086.
Saini S, Tulla K, Maker AV, Burman KD, Prabhakar BS. Therapeutic advances in anaplastic thyroid cancer: a current perspective. Mol Cancer. 2018;17(1):154. https://doi.org/10.1186/S12943-018-0903-0.
Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol. 2000;11(9):1083‐1089. https://doi.org/10.1023/A:1008322002520.
Venkatesh YS, Ordonez NG, Schultz PN, Hickey RC, Goepfert HSNA. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer. 1990;66(2):321‐330.
Bible KC, Kebebew E, Brierley J, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2021;31(3):337‐386. https://doi.org/10.1089/THY.2020.0944.
Maniakas A, Dadu R, Busaidy NL, et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000‐2019. JAMA Oncol. 2020;6(9):1397‐1404. https://doi.org/10.1001/jamaoncol.2020.3362.
Oishi N, Kondo T, Ebina A, et al. Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation. Mod Pathol. 2017;30(11):1527‐1537. https://doi.org/10.1038/MODPATHOL.2017.75.
Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126(3):1052‐1066. https://doi.org/10.1172/JCI85271.
Han JM, Kim WB, Kim TY, et al. Time trend in tumour size and characteristics of anaplastic thyroid carcinoma. Clin Endocrinol (Oxf). 2012;77(3):459‐464. https://doi.org/10.1111/J.1365-2265.2012.04396.X.
Albores‐Saavedra J, Henson DE, Glazer E, Schwartz AM. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype–papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol. 2007;18(1):1‐7. https://doi.org/10.1007/S12022-007-0002-Z.
Glaser SM, Mandish SF, Gill BS, Balasubramani GK, Clump DA, Beriwal S. Anaplastic thyroid cancer: prognostic factors, patterns of care, and overall survival. Head Neck. 2016;38(suppl 1):E2083‐E2090. https://doi.org/10.1002/HED.24384.
Yoshida A, Sugino K, Sugitani I, Miyauchi A. Anaplastic thyroid carcinomas incidentally found on postoperative pathological examination. World J Surg. 2014;38(9):2311‐2316. https://doi.org/10.1007/S00268-014-2536-9.
Chintakuntlawar AV, Yin J, Foote RL, et al. A phase 2 study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer. Thyroid. 2019;29(11):1615‐1622. https://doi.org/10.1089/thy.2019.0086.
Wirth LJ, Brose MS, Sherman EJ, et al. Open‐label, single‐arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer. J Clin Oncol. 2021;39(21):2359‐2366. https://doi.org/10.1200/JCO.20.03093.
Lee NY, Riaz N, Wu V, et al. A pilot study of durvalumab (MEDI4736) with tremelimumab in combination with image‐guided stereotactic body radiotherapy in the treatment of metastatic anaplastic thyroid cancer. Thyroid. 2022;32(7):799‐806. https://doi.org/10.1089/thy.2022.0050.
Koyama S, Miyake N, Fujiwara K, et al. Lenvatinib for anaplastic thyroid cancer and lenvatinib‐induced thyroid dysfunction. Eur Thyroid J. 2018;7(3):139‐144. https://doi.org/10.1159/000485972.
Capdevila J, Wirth LJ, Ernst T, et al. PD‐1 blockade in anaplastic thyroid carcinoma. J Clin Oncol. 2020;38(23):2620‐2627. https://doi.org/10.1200/JCO.19.02727.
Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600‐mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7‐13. https://doi.org/10.1200/JCO.2017.73.6785.
Dierks C, Seufert J, Aumann K, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated Thyroid carcinoma. Thyroid. 2021;31(7):1076‐1085. https://doi.org/10.1089/thy.2020.0322.
Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22(11):1104‐1139. https://doi.org/10.1089/thy.2012.0302.
Li P, Ding Y, Liu M, Wang W, Li X. Sex disparities in thyroid cancer: a SEER population study. Gland Surg. 2021;10:3200‐3210. https://doi.org/10.21037/gs-21-545.
Gild ML, Tsang VHM, Clifton‐Bligh RJ, Robinson BG. Multikinase inhibitors in thyroid cancer: timing of targeted therapy. Nat Rev Endocrinol. 2021;17(4):225‐234. https://doi.org/10.1038/s41574-020-00465-y.
Yu AC, Han AY, Cronkite DA, Sajed D, St John MA. Anaplastic transformation of differentiated thyroid carcinoma. Laryngoscope. 2023;133(2):437‐442. https://doi.org/10.1002/lary.30277.
Rashid M, Agarwal A, Pradhan R, et al. Genetic alterations in anaplastic thyroid carcinoma. Indian J Endocrinol Metab. 2019;23(4):480‐485. https://doi.org/10.4103/ijem.IJEM_321_19.
Latteyer S, Tiedje V, Konig K, et al. Targeted next‐generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer. Endocrine. 2016;54(3):733‐741. https://doi.org/10.1007/s12020-016-1080-9.
Di Como CJ, Urist MJ, Babayan I, et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res. 2002;8(2):494‐501.
Massion PP, Taflan PM, Jamshedur Rahman SM, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res. 2003;63(21):7113‐7121.
Zaika AI, El‐Rifai W. The role of p53 protein family in gastrointestinal malignancies. Cell Death Differ. 2006;13(6):935‐940. https://doi.org/10.1038/sj.cdd.4401897.
Park BJ, Lee SJ, Kim JI, et al. Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res. 2000;60(13):3370‐3374.
Grisanzio C, Signoretti S. p63 in prostate biology and pathology. J Cell Biochem. 2008;103(5):1354‐1368. https://doi.org/10.1002/jcb.21555.
Min IM, Shevlin E, Vedvyas Y, et al. CAR T therapy targeting ICAM‐1 eliminates advanced human thyroid tumors. Clin Cancer Res. 2017;23(24):7569‐7583. https://doi.org/10.1158/1078-0432.CCR-17-200.
Milosevic Z, Pesic M, Stankovic T, et al. Targeting RAS‐MAPK‐ERK and PI3K‐AKT‐mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma. Transl Res. 2014;164(5):411‐423. https://doi.org/10.1016/j.trsl.2014.06.005.
Anforth R, Liu M, Nguyen B, et al. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol. 2014;55(4):250‐254. https://doi.org/10.1111/ajd.12124.